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Abstract
Background: Despite being present in up to 1% of the population, few controlled trials have examined the efficacy
of treatments for bipolar II depression. Pooled data are presented from four placebo-controlled studies (BOLDER I
[5077US/0049] and II [D1447C00135]; EMBOLDEN I [D1447C00001] and II [D1447C00134]) that evaluated the efficacy
of quetiapine monotherapy for depressive episodes in patients with bipolar II disorder.
Methods: All studies included an 8-week, double-blind treatment phase in which patients were randomly assigned
to treatment with quetiapine 300 mg/day, quetiapine 600 mg/day, or placebo. Outcome measures included the
change from baseline in MADRS total score at week 8, effect sizes, and MADRS response and remission rates.
Results and discussion: Improvements in mean MADRS total scores from baseline to week 8 were significantly
greater with quetiapine 300 and 600 mg/day (−15.58 [n = 283] and −14.88 [n = 289]; p < 0.001) compared with
placebo (−11.61 [n = 204]). The MADRS effect sizes were 0.44 for quetiapine 300 mg/day and 0.47 for 600 mg/day
(p < 0.001 vs placebo). Significantly higher proportions of patients receiving quetiapine, at both doses, than
placebo-treated patients achieved response and remission at week 8 (p < 0.01). Common adverse events associated
with quetiapine (both doses) included dry mouth, somnolence, sedation, dizziness, and headache. Rates of mania
and hypomania were similar for quetiapine and placebo. Quetiapine monotherapy demonstrated significant efficacy
compared with placebo and was generally well tolerated in the treatment of bipolar II depression.
Keywords: Bipolar II depression; Efficacy; Monotherapy; Quetiapine; Tolerability
Background
Using Diagnostic and Statistical Manual of Mental Dis-
orders, Fourth Edition (DSM-IV) criteria, the reported
lifetime prevalence of bipolar II disorder (1.0%) is similar
to the estimate for bipolar I disorder (1.1%) (Merikangas
et al. 2007). Moreover, sub-threshold bipolar II disorder
has been estimated to affect up to 6.7% of the general
population (Angst et al. 2010). The prevalence of bipolar
II disorder in clinical practice may well be underestimated.
Temporally, depression usually precedes hypomania (Berk
et al. 2007). The recent BRIDGE study supports earlier ob-
servations that bipolar II disorder may be misdiagnosed as
major depressive disorder (Angst et al. 2012) and, in a
large cohort study, at least 86% of patients whose diagno-
sis changed from major depressive disorder to bipolar dis-
order (i.e., approximately 10% of patients) had bipolar II
disorder (Li et al. 2012). In another cohort study, 12.2% of
patients had diagnoses changed from major depressive
disorder to bipolar II disorder over a mean of 17.5 years
(Fiedorowicz et al. 2011).
While the debilitating effects of bipolar I disorder are
well established, the burden imposed by bipolar II dis-
order is gaining increasing recognition (Benazzi 2007;
MacQueen and Young 2001; Valtonen et al. 2005).
Among patients with bipolar II disorder, the risk of sui-
cide, comorbidity, and role impairment is generally com-
parable with that of bipolar I disorder (Angst et al. 2010;
Merikangas et al. 2011; Suppes and Dennehy 2002;
* Correspondence: allan.young@kcl.ac.uk
1Department of Psychiatry, Imperial College, London SW7 2AZ, UK
13Centre for Affective Disorders, Institute of Psychiatry, King’s College,
London WC2R 2LS, UK
Full list of author information is available at the end of the article
© 2013 Young et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Young et al. International Journal of Bipolar Disorders 2013, 1:10
http://www.journalbipolardisorders.com/content/1/1/10
Valtonen et al. 2005). The authors of the BRIDGE study
have suggested that bipolar II disorder is even more per-
nicious than hitherto appreciated (Angst et al. 2011).
They reported higher rates of comorbid anxiety in bipo-
lar II disorder compared with bipolar I disorder and
higher rates of anxiety disorders, eating disorders, sub-
stance use, suicide, and borderline personality comorbid-
ity in bipolar II disorder than for unipolar disorder
(Angst et al. 2011).
Depression is the prevailing phase of illness in patients
with bipolar II disorder (Judd et al. 2003; Kupka et al.
2007). In a prospective study of treated patients, the per-
centage of time spent in depression was 37.0% for bi-
polar II disorder versus 36.0% for bipolar I disorder
patients compared with 10% and 12.5% of the time with
mania/hypomania, respectively (Kupka et al. 2007). The
depression/mania ratios for patients with bipolar I and II
disorder were of a similar magnitude, suggesting similar
tendencies toward mood instability in the two groups.
Depressive symptoms in bipolar disorder have a substan-
tial impact on patients’ quality of life and their ability to
function in everyday activities (Rosa et al. 2010; Simon
et al. 2007).
There has been a paucity of evidence regarding the
treatment of bipolar II depression, and, in consequence,
there are few consensus recommendations for the man-
agement of these patients (Swartz and Thase 2011).
Older guidelines have generally adapted recommenda-
tions for bipolar I disorder, although more recent guide-
lines have considered bipolar II depression separately
using the extant evidence base (American Psychiatric
Association 2002; Goodwin 2003, 2009; Grunze et al.
2010; Keck et al. 2004; Yatham et al. 2013). Emerging
reports support the effectiveness of several therapies in
the treatment of acute bipolar II depression (Cruz et al.
2010; Swartz and Thase 2011). Among these agents is
quetiapine, which is the only medication approved by
the United States Federal Drug Administration for
monotherapy of both bipolar I and II disorder depressive
episodes (Seroquel Prescribing Information 2012).
The antidepressant efficacy of quetiapine monotherapy
(300 and 600 mg/day) in bipolar I and II depression was
established in two pivotal, 8-week, placebo-controlled
clinical trials, BOLDER (BipOLarDepRession) I and II
(Calabrese et al. 2005; Thase et al. 2006). These findings
were subsequently confirmed in the similarly designed
EMBOLDEN (Efficacy of Monotherapy Seroquel in
BipOLarDepressioN) I and II trials (McElroy et al. 2010;
Young et al. 2010).
The efficacy of quetiapine in patients with bipolar II
depression has been previously reported in a pooled ana-
lysis of the BOLDER I and II studies (Suppes et al. 2008).
The comparable design of the BOLDER and EMBOLDEN
trials facilitated a pooling of the data for patients with
bipolar II depression data to increase the power of the
statistical analyses. In the findings reported herein, the
pooled data from all four studies are used to evaluate the
efficacy of quetiapine (300 and 600 mg/day) monotherapy
in patients with bipolar II depression.
Methods
Study design
This was a pooled analysis of a subpopulation of patients
with bipolar II depression from four randomized, multi-
center, double-blind, fixed-dose monotherapy studies of
quetiapine versus placebo in bipolar I or II depression
(BOLDER I: 5077US/0049, N = 542, patients with bipolar
II depression: n = 182; BOLDER II: D1447C00135, N = 509,
n = 171; EMBOLDEN I: D1447C00001, N = 802, n = 303;
and EMBOLDEN II: D1447C00134, N = 740, n = 262). The
studies were conducted at sites across the USA (BOLDER
I and II) or at centers across the USA, Canada, and else-
where, including sites in Europe, Asia, Turkey, Central and
South America, South Africa, and Australia (EMBOLDEN
I and II). All studies adhered to the current amend-
ment of the Declaration of Helsinki and the International
Conference on Harmonisation/Good Clinical Practice
guidelines. Prior approvals of the study protocols and
amendments were received from either a central institu-
tional review board or a review board at the study site.
Written informed consent was obtained from all patients
prior to study participation.
Details on the study design have been reported previ-
ously (Calabrese et al. 2005; McElroy et al. 2010; Thase
et al. 2006; Young et al. 2010). Briefly, the design of each
of the four studies encompassed 8 weeks of double-blind
treatment whereby patients were randomized to receive
quetiapine (300 or 600 mg/day) or placebo. Additionally,
the EMBOLDEN studies included the active compara-
tors, lithium 600 to 1,800 mg/day (EMBOLDEN I) or
paroxetine 20 mg/day (EMBOLDEN II) to gauge assay
sensitivity (i.e., comparison vs placebo). Data from these
active treatment groups have been reported previously
(McElroy et al. 2010; Young et al. 2010). A continuation
phase of 26 to 52 weeks’ duration also formed the design
of the EMBOLDEN studies, the results for which
have been reported previously (Young et al. 2012).
Randomization in the studies was achieved using an inter-
active voice-response central randomization system, and
numbers were not sequential within a site. No member of
the investigational teams had access to the randomization
schemes during the conduct of the studies. All treatment
packaging was identical, with placebo and active tablets
identical in appearance and number.
Patient population
Eligible patients were adult outpatients aged between 18
and 65 years with a diagnosis of bipolar I or II disorder,
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most recent episode depressed as defined by DSM-IV
(American Psychiatric Association 2000), with or without
a rapid-cycling course (≥4 episodes to ≤8 episodes per
year). Only patients with bipolar II disorder were included
in the current analysis. Study participants were also re-
quired to have a Hamilton Rating Scale for Depression
(Hamilton 1960) (HAM-D) total score ≥20, a HAM-D
item 1 (depressed mood) score ≥2, and a Young Mania
Rating Scale (Young et al. 1978) (YMRS) score ≤12.
The key exclusion criteria in the four studies were a
current depressive episode >12 months’ or <4 weeks’
duration at enrollment; an Axis I disorder diagnosis
other than bipolar disorder; ≥8 mood episodes in the
preceding 12 months (except BOLDER I); a HAM-D
Item 3 score ≥3, posing a serious suicidal or homicidal
risk (as judged by the investigator), or attempted suicide
within the past 6 months. In addition, a history of
nonresponse to an adequate treatment period (6 weeks)
with ≥2 classes of antidepressants during the current
episode or previous nonresponse to the study treatments
(as determined by the investigator); substance depend-
ence (DSM-IV) or abuse; or a clinically relevant medical
condition led to exclusion from the study.
Current antipsychotic, antidepressant, and mood-
stabilizing medications were discontinued in a washout
period of at least 5 to 28 days. In each study, patients
were randomly assigned to once-daily quetiapine or
matching placebo, which was administered orally at bed-
time. An initial quetiapine dose of 50 mg/day was subse-
quently increased in 100-mg increments to achieve a
final target dose of 300 or 600 mg/day at day 4 or day 8,
respectively. Concomitant treatment with all other psy-
chotropic drugs was prohibited during the study, with
the exception of hypnotics (zolpidem tartrate up to
10 mg/day [all studies] and zaleplon up to 20 mg/day,
zopiclone up to 7.5 mg/day, or chloral hydrate up to
1 g/day [EMBOLDEN I and II]) at bedtime for insomnia
and lorazepam (up to 3 mg/day) for severe anxiety. Hyp-
notics and lorazepam were permitted for the first 3 weeks
of treatment, except in the 8 h before a psychiatric
assessment.
Efficacy assessments
The primary efficacy outcome measure in all four
studies was the change from baseline to week 8 in
Montgomery-Åsberg Depression Rating Scale (MADRS)
total score (Montgomery and Asberg 1979), and this is
consequently utilized in the current post hoc analysis.
Secondary efficacy measures included the change in
MADRS individual items, MADRS response (defined
as a decrease from baseline of ≥50% in MADRS total
score) and remission (defined as MADRS total score
of ≤12) rates, HAM-D total scores and Hamilton Rating
Scale for Anxiety (Hamilton 1959) (HAM-A) total scores
at week 8. Additional post hoc efficacy endpoints were the
evaluation of effect sizes and number-needed-to-treat
(NNT). Data from analyses of patient-reported outcome
measures of functioning and quality of life have been
reported elsewhere (Gustafsson and Fajutrao 2011). Effi-
cacy assessments were performed at baseline and weekly
(BOLDER I and II) or every 2 weeks (EMBOLDEN I and
II) until week 8.
Safety assessments
Safety and tolerability assessments included the inci-
dence and severity of adverse events and discontinua-
tions because of adverse events, which were recorded at
each visit. Adverse events were classified according to the
Medical Dictionary for Regulatory Activities (MedDRA)
terminology. Additional measures were the proportion
of patients experiencing treatment-emergent mania/
hypomania (defined as a YMRS total score ≥16 on two
consecutive assessments or at final assessment, or an ad-
verse event report of treatment-emergent mania or hypo-
mania) and the incidence of adverse events potentially
associated with extrapyramidal symptoms (EPS; including
akathisia, cogwheel rigidity, dyskinesia, dystonia, extrapyr-
amidal disorder, freezing phenomenon, hypertonia, muscle
contractions involuntary, muscle rigidity, psychomotor
hyperactivity, restlessness, tardive dyskinesia, and tremor).
Other safety parameters comprised weight, clinical labora-
tory parameters using fasting and nonfasting samples,
physical examination, and vital signs.
Statistical analyses
Data for patients with a diagnosis of bipolar II depres-
sion in the BOLDER I and II and EMBOLDEN I and II
studies were pooled in order to enhance the precision of
the statistical analyses. Efficacy analyses were conducted
in the pooled intent-to-treat (ITT) population (patients
who received at least one dose of study medication and
had at least one post-baseline efficacy assessment) using
last observation carried forward (LOCF) methodology.
Changes from baseline in primary and secondary efficacy
measures for quetiapine 300 or 600 mg/day versus
placebo were evaluated using analysis of covariance
(ANCOVA) with baseline score as the covariate, treat-
ment and bipolar diagnosis strata as fixed effects, and
country (EMBOLDEN I and II) or center (BOLDER I
and II) as a random effect. The relationship between
severity (MADRS total score at baseline) and treat-
ment response (MADRS total score at the end of
treatment) was investigated in an exploratory analysis
of the ITT population by plotting the individual data
and superimposing linear regression lines based on an
ANCOVA with baseline score as the covariate and treat-
ment as a fixed effect. Probability levels (p < 0.05, p < 0.01,
p < 0.001) are provided; however, these should be viewed
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with caution due to the post hoc nature of this analysis. It
should also be noted that the probability levels were not
adjusted for multiplicity.
Categorical changes, such as MADRS response and
remission, were analyzed with the Cochran-Mantel-
Haenszel test. Effect sizes, assessed using mixed-model
repeated measures (MMRM) methodology based on
observed cases data, were calculated as the improve-
ment in quetiapine score versus placebo divided by
the pooled standard deviation (SD). The NNT in order to
achieve response was calculated according to the formula:
1/(number of placebo responders - number of quetiapine
responders); an equivalent formula calculated the NNT
to achieve remission. An NNT of 1 would indicate
that all patients in the quetiapine group were responders/
remitters compared with none of the patients in the pla-
cebo group. Analyses of safety variables were performed
on the pooled safety population (i.e., patients who received
at least one dose of the study medication) and were
presented descriptively.
Results
Patient disposition is shown in Figure 1. A total of 776
(35.2%) patients with bipolar II depression were included
in the ITT population (283, 289, and 204 patients re-
ceived quetiapine 300 mg/day, quetiapine 600 mg/day, or
placebo, respectively). The safety population comprised
819 patients with bipolar II depression (298, 307, and 214
patients received quetiapine 300 mg/day, quetiapine
600 mg/day, or placebo, respectively), representing 35.4%
of the total pooled safety population of patients with bipo-
lar I or II depression from the four studies (N = 2,314).
At baseline, the demographic and clinical characteris-
tics were similar among treatment groups (Table 1). The
baseline symptom severity scores indicated a patient
population with moderate to severe depression without
mania symptoms.
Primary efficacy outcome: Montgomery-Åsberg
depression rating scale total score
Among patients with bipolar II disorder, treatment with
quetiapine resulted in significantly greater improvements
in depression symptoms compared with placebo, as
measured by mean change in MADRS total score from
baseline to week 8 (mean [SE] −15.58 [0.62] and −14.88
[0.62] for quetiapine 300 and 600 mg/day, respectively,
vs−11.61 [0.70] for placebo; LOCF; p < 0.001, both
doses). Significant separation from placebo was observed
from week 1 for both doses of quetiapine and was
maintained through week 8 (Figure 2). Effect sizes, based
on MADRS scores, were moderate for both quetiapine
300 and 600 mg/day (MMRM: 0.44 and 0.47, respect-
ively, p < 0.001 vs placebo; Figure 3). The effect sizes
in the bipolar I population in the four trials were 0.58
for quetiapine 300 mg/day and 0.64 for quetiapine
600 mg/day (Figure 3).
Patients with bipolar II disorder stratified by a rapid-
(≥4 mood episodes per year) or nonrapid-cycling course
also demonstrated significant improvements in MADRS
total score at week 8. Among patients without a rapid-
cycling course, MADRS total score improved signifi-
cantly by a mean (SE) of 15.18 (0.67) and 14.25 (0.66)
with quetiapine 300 and 600 mg/day compared with
11.58 (0.75) points for placebo (p < 0.001 and p =
0.005 for quetiapine 300 and 600 mg/day, respect-
ively) at week 8. Significant symptomatic improve-
ments at week 8 were also observed in patients with
rapid cycling: 16.80 (1.63) and 16.92 (1.71) for
quetiapine 300 and 600 mg/day versus 11.12 (1.95)
for placebo (p = 0.011 and p = 0.012, respectively). In
the exploratory analysis of the relationship between
MADRS total score at baseline and end of treatment,
there was an indication that the difference between
placebo and both quetiapine doses at end of treat-
ment increased as baseline score increased (Table 2;
Figure 4). However, given the post hoc and explora-
tory nature of this analysis where the studies were
not designed for this purpose, no formal inference
can be made.
Secondary efficacy outcomes
MADRS item analyses
Following 8 weeks of treatment, quetiapine at doses of
300 and 600 mg/day was associated with significant im-
provements in the majority of the individual MADRS
items when compared with placebo (p < 0.05 vs placebo,
Figure 5), with the exceptions of apparent sadness for
quetiapine 300 mg/day, and concentration difficulties and
lassitude for 600 mg/day. From week 4 onward, there were
significantly greater improvements in MADRS Item 10
(suicidal thoughts) scores with both doses of quetiapine
(p < 0.05 vs placebo).
MADRS response and remission
By week 8, significantly higher proportions of patients
treated with quetiapine 300 and 600 mg/day had
achieved response and remission when compared with
placebo. Among quetiapine-treated patients, 64.7%
(300 mg/day) and 62.6% (600 mg/day) were classified as
responders at week 8 compared with 49.0% of placebo-
treated patients (p < 0.001 and p < 0.01 for 300 and
600 mg/day, respectively; ITT, LOCF). When compared
with placebo (46.1%), significantly more quetiapine-
treated patients met remission criteria at week 8 (65.0%
and 61.9%, respectively; p < 0.001 vs placebo; ITT,
LOCF). At week 8, NNT for response and remission
were 6 and 5 for quetiapine 300 mg/day and 7 and 6 for
quetiapine 600 mg/day, respectively.
Young et al. International Journal of Bipolar Disorders 2013, 1:10 Page 4 of 12
http://www.journalbipolardisorders.com/content/1/1/10
Hamilton rating scale for depression total score
Patients who were treated with quetiapine 300 and
600 mg/day demonstrated significantly greater improve-
ments in HAM-D total score from week 1 through week
8 compared with placebo (p < 0.001; ITT, LOCF). At
week 8, HAM-D total scores improved by a mean (SE)
of 14.00 (0.49) and 13.57 (0.49) points for quetiapine 300
and 600 mg/day, respectively, versus 10.88 (0.55) for
placebo (p < 0.001).
Hamilton rating scale for anxiety total score
Following quetiapine treatment, patients demonstrated
significant improvements in symptoms of anxiety, as mea-
sured by mean change from baseline in HAM-A total
score at week 8 (p < 0.05 both doses vs placebo; Figure 6).
Significant improvements in HAM-A total score with
quetiapine 300 and 600 mg/day versus placebo were ob-
served from week 1 onward (−9.62 [p < 0.001] and −8.89
[p < 0.05] vs −7.34 at week 8, respectively; ITT, LOCF).
Safety
Overall rates of adverse events in the pooled safety
population were 73.8%, 74.3%, and 67.8% for the
quetiapine 300 mg/day, 600 mg/day, and placebo arms,
respectively. As shown in Table 3, common adverse
events associated with quetiapine 300 and 600 mg/day
included dry mouth, somnolence, sedation, and dizzi-
ness. Adverse events potentially related to extrapyram-
idal symptoms were observed in 12.4%, 8.8%, and 6.1%
of the quetiapine 300 mg/day, quetiapine 600 mg/day,
and placebo groups, respectively. Rates of treatment-
emergent mania/hypomania during acute treatment
were similar among the treatment groups: 1.3%, 3.3%,
and 2.3% for quetiapine 300 mg/day, 600 mg/day, and
placebo arms, respectively. Rates of discontinuation
because of adverse events were 12.1% for quetiapine
300 mg/day, 17.9% for quetiapine 600 mg/day, and 5.1%
for placebo. Changes from baseline in weight and
Table 1 Baseline demographic and clinical characteristics
(safety population)
Quetiapine
300 mg/day
(n = 298)
Quetiapine
600 mg/day
(n = 307)
Placebo
(n = 214)
Gender,%
Male 36.9 39.7 37.4
Female 63.1 60.3 62.6
Age, mean (years) 38.4 39.4 37.7
Weight, mean (kg) 79.7 80.1 78.9
BMI, mean 28.0 28.0 27.8
Symptom rating,
mean total score
MADRS 27.8 27.5 28.0
HAM-D 24.2 24.0 24.2
YMRS 4.5 4.5 5.0
HAM-A 19.2 18.6 19.1
Figure 1 Patient disposition.
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laboratory parameters during acute treatment are
presented in Table 4. Although average weight gain was
only about 1 kg greater in the two groups receiving
quetiapine, the proportions of patients in both arms
gaining at least 7% body weight was higher in both
quetiapine arms (Table 4).
Discussion
To our knowledge this pooled post hoc analysis of pa-
tients with bipolar II disorder experiencing an acute
episode of depression represents the largest population
available for evaluation to date. Quetiapine monotherapy
at doses of 300 and 600 mg/day was significantly more
effective than placebo at reducing the symptoms of de-
pression as assessed by the change in MADRS total
score. The improvements during quetiapine treatment
were observed at week 1 and were sustained up to week
8. Significant improvements in 9 and 8 of the 10
MADRS individual items were apparent with quetiapine
300 and 600 mg/day, respectively, indicating the efficacy
Figure 3 Effect sizes of quetiapine 300 and 600 mg/day in patients with bipolar I or bipolar II disorder.
Figure 2 Mean change from baseline to week 8 in MADRS total score (ITT population; LOCF).
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of quetiapine over a broad range of depressive symp-
toms. An exploratory analysis indicated that the differ-
ence between placebo and both doses of quetiapine at the
end of treatment increased with initial severity (i.e., base-
line MADRS total score). Across all analyses, the lower
dose was as effective as the higher dose in patients with
bipolar II disorder and tended to be associated with lower
reports of adverse events.
The findings of this pooled analysis are fully consistent
with those of the individual trials in which both doses of
quetiapine were associated with statistically or numeric-
ally greater improvements in MADRS total score com-
pared with placebo in the bipolar II subgroups. In the
EMBOLDEN II and BOLDER II trials, quetiapine 300
and 600 mg/day resulted in significant improvements in
MADRS total score from week 1 or 2 through to week
8, whereas in the EMBOLDEN I and BOLDER I trials
there were no significant differences between either
quetiapine dose and placebo at week 8 although there
were significant differences from placebo at earlier
assessments. This latter result may be explained by the
relatively low power of the subanalyses in each of the
trials, where the predominant number of patients had
bipolar I rather than bipolar II depression.
Although these studies observed a relatively high pla-
cebo remission rate (46.1%), the remission rate for each
dose of quetiapine (65.0% and 61.9% for quetiapine 300
and 600 mg/day, respectively) was nevertheless signifi-
cantly higher and indicated that the benefit of active
quetiapine was clinically significant. The effect sizes in
the bipolar II population of the four quetiapine trials
were moderate for both quetiapine 300 and 600 mg/day
(0.44 and 0.47, respectively). In comparison, the effect
sizes in the bipolar I population were also moderate but
numerically higher (0.58 for quetiapine 300 mg/day
and 0.64 for quetiapine 600 mg/day). A high placebo
response rate has also been observed in other trials of
agents evaluated in bipolar depression (Calabrese et al.
2008; Thase et al. 2008). Confirming the antidepressant
efficacy observed on the MADRS scale, both doses of
Figure 4 Relationship between MADRS total score at baseline and of treatment (ITT).
Table 2 Relationship between MADRS total score at baseline and of treatment (ITT) (ANCOVA with baseline score as
covariate and treatment as fixed effect)
Treatment Dependent variable Fixed factor Estimate Degrees of freedom t value p value
Quetiapine 300 mg/day MADRS at end of treatment Intercept −0.242 281 −0.11 0.9119
MADRS at baseline 0.445 281 5.86 <0.0001
Quetiapine 600 mg/day MADRS at end of treatment Intercept 1.127 287 0.53 0.5998
MADRS at baseline 0.423 287 5.59 <0.0001
Placebo MADRS at end of treatment Intercept −4.302 202 −1.26 0.2086
MADRS at baseline 0.741 202 6.23 <0.0001
Young et al. International Journal of Bipolar Disorders 2013, 1:10 Page 7 of 12
http://www.journalbipolardisorders.com/content/1/1/10
quetiapine were associated with significantly greater im-
provements in HAM-D total score from week 1 through
week 8.
The broad therapeutic profile of quetiapine is demon-
strated by the symptomatic improvements in patients
with rapid cycling, who typically represent a manage-
ment challenge (Bauer et al. 2008; Kupka et al. 2005; Lee
et al. 2010), and may be particularly common in bipolar
II (Berk and Dodd 2004; Kupka et al. 2003). A planned
subanalysis of the BOLDER I study indicated that
quetiapine was as effective in bipolar I or II patients with
a history of rapid cycling as it was in patients with
nonrapid cycling (Vieta et al. 2007). The current pooled
analysis extends these observations by demonstrating
significant decreases in MADRS total score at week 8
with both quetiapine doses both in patients with bipolar
II depression who have rapid cycling and in those with
less frequent episodes.
Comorbid anxiety is common among bipolar II pa-
tients and can have a large, adverse impact on treatment
response, functioning, and quality of life (Angst et al.
2011; Gao et al. 2008; Judd et al. 2003; Otto et al. 2006).
In the combined BOLDER I and II trials, quetiapine was
effective in the treatment of bipolar I and II depression
regardless of the severity of baseline anxiety (Lydiard
et al. 2009). Patients with bipolar II depression in the
Figure 6 Mean change from baseline to week 8 in HAM-A total score (ITT population; LOCF).
Figure 5 Difference in mean change from baseline in MADRS individual item scores at week 8 (ITT population; LOCF).
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BOLDER I trial did not show a statistically significant
difference in HAM-A total score from placebo
(Hirschfeld et al. 2006), which again may have been due
to the smaller number of patients available for analysis.
Quetiapine treatment resulted in significant improve-
ments in the symptoms of anxiety in the current analysis
among this larger population with bipolar II depression,
the majority of whom had mild-to-moderate anxiety at
baseline.
The reductions in symptom severity during quetiapine
treatment in patients with bipolar II depression are
accompanied by improvements in patient-reported
outcomes. Pooled findings from the BOLDER and
EMBOLDEN trials showed clear improvements with
both doses of quetiapine in overall functioning, indi-
vidual domains of social and occupational functioning,
as well as quality of life (Gustafsson and Fajutrao
2011). These results are particularly promising given
that a diagnosis of bipolar II disorder is associated
with poor health-related quality of life even during
periods of euthymia (Maina et al. 2007).
Quetiapine was tested in the four EMBOLDEN and
BOLDER studies under rigorous conditions. The only
other agent that has been tested under similarly robust
circumstances in bipolar II depression is lamotrigine,
and the data are inconsistent among studies (Swartz and
Thase 2011). Among other treatments tested in bipolar
II depression, the data for lithium, antidepressants
(selective serotonin re-uptake inhibitors), N-acetyl cyst-
eine, and pramipexole are suggestive of efficacy but not
conclusive (Magalhaes et al. 2011; Swartz and Thase
2011). Further studies are required to establish the rela-
tive therapeutic position of these agents in the bipolar II
disorder treatment armamentarium, with long-term
trials being essential.
One implication of demonstrating that a medication
has efficacy as an acute phase therapy is the need to
document longer-term benefit for relapse prevention.
The continuation phase of the EMBOLDEN studies
included 231 patients with bipolar II depression who
received quetiapine for 26 to 52 weeks and is one of the
largest bipolar II patient populations studied in a con-
tinuation phase trial (Young et al. 2012). Quetiapine was
associated with a reduced risk of any mood event or
depressive relapse compared with placebo (Young et al.
2012), suggesting that it is an efficacious treatment in
both the short and long term in patients with bipolar II
depression.
The safety and tolerability profile of quetiapine is well
established in clinical trials. In this analysis of patients
with bipolar II depression, safety results during acute
treatment with quetiapine were in line with observations
in the individual BOLDER and EMBOLDEN patient
populations (Calabrese et al. 2005; McElroy et al. 2010;
Thase et al. 2006; Young et al. 2010). The adverse event
profile in this patient population was qualitatively similar
to findings in acute and maintenance studies of quetiapine
monotherapy in patients with bipolar I or II disorder
(Bowden et al. 2005; McIntyre et al. 2005; Weisler et al.
2011). However, patients with bipolar II disorder are
thought to be more sensitive to side effects than bipolar I
disorder patients. In the combined BOLDER I and II trials,
the rate of discontinuation from quetiapine due to any
adverse event was slightly higher among bipolar II dis-
order patients than for those with bipolar I disorder
(Suppes et al. 2008).
Overall, there were changes in some glucose and lipid pa-
rameters and increases in weight with quetiapine, which
were consistent with previous observations (Calabrese et al.
2005; McElroy et al. 2010; Thase et al. 2006; Young et al.
2010). The prescribing information for quetiapine recom-
mends appropriate clinical monitoring for alterations in
Table 4 Weight, glucose, and lipid data (all samples;
safety population)
Mean change from
randomization (SD)a
Quetiapine
300 mg/day
(n = 298)
Quetiapine
600 mg/day
(n = 307)
Placebo
(n = 214)
Total cholesterol (mg/dL) −2.3 (2.1) 0.8 (2.0) −3.5 (2.5)
LDL cholesterol (mg/dL) −5.3 (1.7) −0.3 (1.7) −4.4 (1.9)
HDL cholesterol (mg/dL) −0.5 (0.6) −1.6 (0.6) −1.0 (0.7)
Triglycerides (mg/dL) 21.4 (5.9) 14.2 (4.9) 9.0 (7.4)
Glucose (mg/dL) 3.3 (1.0) 2.8 (0.9) 1.8 (1.1)
Insulin (pmol/L) 31.0 (8.4) 24.2 (6.1) 12.5 (8.5)
Mean weight change, kg (SE) 1.0 (0.19) 1.1 (0.23) 0.0 (0.17)
Weight change ≥7%, n (%) 17 (6.5) 24 (9.7) 4 (2.2)
aMean change from randomization to continuation phase to the end
of treatment.
Table 3 Common adverse events (≥5% of patients in any
group; safety population)
Adverse
event, N (%)
Quetiapine
300 mg/day
(n = 298)
Quetiapine
600 mg/day
(n = 307)
Placebo
(n = 214)
Dry mouth 94 (31.5) 90 (29.3) 21 (9.8)
Somnolence 65 (21.8) 60 (19.5) 18 (8.4)
Sedation 60 (20.1) 59 (19.2) 12 (5.6)
Dizziness 39 (13.1) 48 (15.6) 12 (5.6)
Headache 27 (9.1) 37 (12.1) 40 (18.7)
Fatigue 26 (8.7) 30 (9.8) 14 (6.5)
Constipation 24 (8.1) 24 (7.8) 9 (4.2)
Nausea 23 (7.7) 22 (7.2) 21 (9.8)
Diarrhea 12 (4.0) 8 (2.6) 17 (7.9)
Insomnia 8 (2.7) 2 (0.7) 14 (6.5)
Upper respiratory tract infection 7 (2.3) 7 (2.3) 11 (5.1)
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lipids, including blood lipid testing at the beginning
of and periodically during treatment (Seroquel Prescribing
Information 2012). Moreover, any patient treated with
second-generation antipsychotics should be monitored
for symptoms of hyperglycemia including polydipsia,
polyuria, polyphagia, and weakness (Seroquel Prescribing
Information 2012). When starting treatment, patients with
diabetes or risk factors for diabetes should undergo blood
glucose testing before and during treatment (Seroquel
Prescribing Information 2012).
Treatment-emergent mania is a concern during treat-
ment of bipolar depression with conventional antide-
pressants, although the extent to which it occurs in
bipolar II depression remains a matter of debate
(Altshuler et al. 2006; Leverich et al. 2006; Vazquez
et al. 2011). In the current analyses, the rates of
treatment-emergent hypomania/mania were similar for
the two quetiapine doses and for placebo, indicating
that quetiapine poses a minimal risk for affective
switching in patients with bipolar II depression. How-
ever, the incidence of treatment-emergent mania/
hypomania may have been underestimated using the
definition employed in the trials (i.e., a YMRS total
score ≥16 on two consecutive assessments or at final
assessment or an adverse event of mania/hypomania)
as patients with bipolar II disorder who exhibit frank
mania may only do so briefly; moreover, patients who
have a YMRS total score ≥16 on two consecutive as-
sessments may have bipolar I disorder.
There are a number of potential limitations to this
pooled analysis. An important consideration is its post
hoc nature. Furthermore, the generalizability of the find-
ings should be considered in the context of the inclusion
and exclusion criteria of the BOLDER and EMBOLDEN
trials. The patients in these studies had few significant
co-morbidities and were likely to have a low risk of
suicide, although this may not be the case in all patients
with bipolar disorder (Perugi et al. 2013). The analysis was
based on 8-week studies and gives an insight into the
short-term safety and tolerability of quetiapine in this
population. Longer-term information is provided by the
continuation phase of the EMBOLDEN studies, which
included patients with bipolar II depression who received
quetiapine for up to 52 weeks (Young et al. 2012).
Conclusions
These analyses on the largest sample of patients with
bipolar II depression studied to date support the efficacy
and tolerability of quetiapine 300 and 600 mg/day in
treating bipolar II depression.
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